• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference.

作者信息

Marcec Robert, Dodig Vinko Michael, Likic Robert

机构信息

School of Medicine, University of Zagreb, Zagreb, Croatia.

School of Medicine, University of Zagreb, Zagreb, Croatia; Department of Internal Medicine, Clinical Hospital Centre Zagreb, Unit for Clinical Pharmacology, Kispaticeva 12, Zagreb 10000, Croatia.

出版信息

J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.011. Epub 2022 Nov 18.

DOI:10.1016/j.jinf.2022.11.011
PMID:36403698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9673087/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/444d/9673087/37563c06e962/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/444d/9673087/37563c06e962/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/444d/9673087/37563c06e962/gr1_lrg.jpg

相似文献

1
A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference.一项关于氟伏沙明与新冠病毒疾病（COVID-19）患者住院风险的荟萃分析：共同发挥作用。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.011. Epub 2022 Nov 18.
2
The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.氟伏沙明治疗 COVID-19 患者的疗效和安全性：一项来自随机对照试验的系统评价和荟萃分析。
PLoS One. 2024 May 16;19(5):e0300512. doi: 10.1371/journal.pone.0300512. eCollection 2024.
3
Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.氟伏沙明用于非住院急性新冠肺炎感染患者及在安慰剂对照试验中降低住院率、机械通气率和死亡率方面缺乏疗效：一项系统评价和荟萃分析
Am J Ther. 2022;29(3):e298-e304. doi: 10.1097/MJT.0000000000001496. Epub 2022 Mar 31.
4
Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.氟伏沙明对非住院 COVID-19 患者结局的影响：系统评价和荟萃分析。
J Infect Public Health. 2022 Nov;15(11):1259-1264. doi: 10.1016/j.jiph.2022.10.010. Epub 2022 Oct 13.
5
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
6
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.氟伏沙明用于 COVID-19 门诊管理以预防住院：系统评价和荟萃分析。
JAMA Netw Open. 2022 Apr 1;5(4):e226269. doi: 10.1001/jamanetworkopen.2022.6269.
7
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.氟伏沙明对症状性 COVID-19 感染成年患者临床恶化的试验序贯分析和更新的荟萃分析。
Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088.
8
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.一项系统评价和荟萃分析，研究了氟伏沙明治疗 COVID-19 病情恶化、死亡和长期 COVID 并发症的剂量和时间疗效。
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
9
Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.氟伏沙明作为门诊治疗 COVID-19 患者的疗效和安全性：临床试验的系统评价和荟萃分析。
Ann Pharmacother. 2023 Dec;57(12):1389-1397. doi: 10.1177/10600280231162243. Epub 2023 Mar 31.
10
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.三种新型口服抗病毒药物（莫努匹韦、氟伏沙明和帕罗韦德）治疗 COVID-19 的疗效和安全性：一项荟萃分析。
Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936.

引用本文的文献

1
The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.氟伏沙明治疗 COVID-19 患者的疗效和安全性：一项来自随机对照试验的系统评价和荟萃分析。
PLoS One. 2024 May 16;19(5):e0300512. doi: 10.1371/journal.pone.0300512. eCollection 2024.
2
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.早期使用氟伏沙明可降低有症状的COVID-19门诊患者临床恶化的风险：一项真实世界的回顾性前后分析。
Microorganisms. 2023 Aug 12;11(8):2073. doi: 10.3390/microorganisms11082073.
3
Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data.
抗抑郁药与新型冠状病毒奥密克戎变异株感染严重程度之间的关系：一项使用真实世界数据的回顾性队列研究
Lancet Reg Health West Pac. 2023 May;34:100716. doi: 10.1016/j.lanwpc.2023.100716. Epub 2023 Feb 27.
4
Overview of the potential use of fluvoxamine for COVID-19 and long COVID.氟伏沙明用于治疗新冠病毒病及新冠后综合征的潜在用途概述。
Discov Ment Health. 2023;3(1):9. doi: 10.1007/s44192-023-00036-3. Epub 2023 Mar 21.
5
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study.乌干达新冠肺炎住院患者中氟伏沙明与死亡率及症状缓解的关联：一项前瞻性干预开放标签队列研究
Mol Psychiatry. 2023 Dec;28(12):5411-5418. doi: 10.1038/s41380-023-02004-3. Epub 2023 Mar 3.